TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

TCRX - 2 Presentations (May 18) tomorrow at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.

https://ca.finance.yahoo.com/news/tscan-therapeutics-announces-upcoming-presentations-210200326.html

Poster Presentation:

Title: Multiplexed TCR-T cell therapy: A strategy to enhance the efficacy of engineered T cell therapy
Presenter: Gavin MacBeath
Poster Number: W-221
Abstract Number: 1095
Session: Cancer – Immunotherapy, Cancer Vaccines III
Date & Time: Wednesday, May 18, 2022 5:30-6:30 p.m. ET
Location: Hall D

Summary: Adoptive Cell Transfer with genetically engineered T cells holds great promise for treating solid tumors, but by targeting only one antigen at a time, complete responses have been rare and are often short-lived due to heterogeneous expression of cancer associated antigens and HLA loss-of-heterozygosity. TScan’s multiplexed TCR-T cell therapy across multiple target antigens and HLA molecules mimics the natural oligoclonal T cell response to cancer and provides a way to address some of the major challenges associated with resistance to adoptive cell therapy. Using two TCRs to target mixed tumor cell cultures with heterogenous antigen expression, synergistic cytotoxicity was achieved in which the presence of one TCR-T/target cell pair enhanced the activity of the other TCR-T against its target; this effect was mediated via secreted soluble factors. The findings support the hypothesis that multiplexed TCR-T has the potential to overcome antigen heterogeneity not only through independent targeting of different target cells in the same tumor, but also by cytokine-mediated enhancement of each T cell’s response.

Oral Presentation:

Title: Discovery of a novel C*07:02-restriced epitope on MAGE-A1 and pre-clinical development of an enhanced TCR-T cell therapy candidate for the treatment of solid tumors
Presenter: Gavin MacBeath
Abstract Number: 852
Session: Cell-based Cancer Immunotherapies II
Date & Time: Wednesday, May 18, 2022 5:00-5:15 p.m. ET
Location: Salon G

Summary: Immune checkpoint therapy can enhance anti-tumor activity of T cells, leading to durable responses in a subset of cancer patients. Using the Company’s proprietary TargetScan platform, the Company identified TCRs and cancer antigens from a head and neck cancer patient who exhibited substantial tumor reduction after only 8 weeks of checkpoint therapy. A TCR directed to a novel C*07:02-restricted epitope of MAGEA1 was identified as a potential driver of the anti-tumor response. These results suggest that TargetScan can identify relevant tumor antigens and TCRs from expanded T cell repertoires of patients exhibiting strong and durable responses to checkpoint therapy, thereby providing suitable TCRs for clinical development. The Company has advanced this TCR-T to IND enabling studies as TSC-204-C07.